Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Wogonin as a targeted therapeutic agent for EBV (+) lymphoma cells involved in LMP1/NF-κB/miR-155/PU.1 pathway

Fig. 3

The expression of LMP1/miR-155/PU.1 in Raji cells with the process of miR-155 inhibitor treated apoptosis. a Effect of miR-155 inhibitor at the concentration of 50, 100 and 200 nmol/L for 48 h on the expression of miR-155 mRNA in Raji cells using PCR detection and analyzed by the ΔCt method, bars were shown as mean ± SD (n = 3) and represent miR-155/U6 ratios relative to the control group. The difference level of significance was (**P < 0.01). NC = Negative Control. Mock (cells + Lipo2000) = Blank Control. b Flow cytometry was used to detect the apoptosis of Raji cells after treated with miR-155 inhibitor at 100 nmol/L for 48 h. The ratio of apoptosis was 8.5 ± 0.74% and 12.94 ± 4.59% for the control and inhibitor-treated groups respectively. c Effect of miR-155 inhibitor at the concentration of 100 nmol/L for 48 h on LMP1 and PU.1 mRNA level of Raji cells detected by PCR and analyzed by the ΔCt method, bars were shown as mean ± SD (n = 3) and represent LMP1/GAPDH or PU.1/GAPDH ratios relative to the control group. The difference level of significance was (*P < 0.05). d Effect of miR-155 inhibitor 100nmol/L for 48 h on LMP1 and PU.1 protein expressions, the protein expression was analyzed by western blots; GAPDH was used as a loading control. e For quantity of (d), images were analyzed using Image J, bars were the mean ± SD (n = 3). The comparisons were made relative to control group, and the difference level of significance was (**P < 0.01)

Back to article page